Cosmo Pharmaceuticals NV
SIX:COPN

Watchlist Manager
Cosmo Pharmaceuticals NV Logo
Cosmo Pharmaceuticals NV
SIX:COPN
Watchlist
Price: 114 CHF -2.23% Market Closed
Market Cap: CHf2B

Net Margin

32.7%
Current
Improving
by 10.3%
vs 3-y average of 22.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
32.7%
=
Net Income
€55.2m
/
Revenue
€182.3m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
32.7%
=
Net Income
CHf55.2m
/
Revenue
€182.3m

Peer Comparison

Country Company Market Cap Net
Margin
IE
Cosmo Pharmaceuticals NV
SIX:COPN
1.8B CHF
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.2B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
220.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
269.2B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.4B USD
Loading...

Market Distribution

Higher than 94% of companies in Ireland
Percentile
94th
Based on 314 companies
94th percentile
32.7%
Low
-6 913.1% — 0%
Typical Range
0% — 10.2%
High
10.2% — 197.7%
Distribution Statistics
Ireland
Min -6 913.1%
30th Percentile 0%
Median 3.1%
70th Percentile 10.2%
Max 197.7%

Cosmo Pharmaceuticals NV
Glance View

Market Cap
2B CHF
Industry
Pharmaceuticals

Cosmo Pharmaceuticals NV, rooted in the picturesque landscapes of Italy but with its headquarters in Ireland for strategic financial maneuvering, has carved a niche for itself within the global pharmaceuticals industry. This specialty pharmaceutical company is dedicated to the development and manufacturing of therapies for gastrointestinal diseases. Cosmo’s forte lies in its proprietary clinical development platform, providing innovative solutions aimed at enhancing gastrointestinal health, covering conditions like inflammatory bowel disease, colon infections, and bowel preparation for colonoscopy. These critical health areas require specialized treatments, and Cosmo leverages its technological prowess through its novel drug delivery technologies such as Methylene Blue MMX and Aemcolo. This focus not only elevates the scientific community’s understanding of GI issues but positions Cosmo at the intersection of research innovation and practical treatment efficacy. Cosmo Pharmaceuticals thrives on a business model that seeks to maximize the potential of its intellectual property and licensing operations. By investing substantially in research and development, the company brings forward its proprietary products which offer targeted therapies, and then participates in strategic partnerships and licensing agreements with larger pharmaceutical companies. By doing so, Cosmo reduces risk and diversifies its revenue channels. This agile strategy allows them to earn royalties and revenue through commercialization deals, placing them in a financial position of strength without having to shoulder the full burden of global marketing and distribution. The company’s ability to merge scientific ingenuity with strategic business acumen underscores its journey from a regional player to a notable name on the international pharmaceutical stage.

COPN Intrinsic Value
170.44 CHF
Undervaluation 33%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
32.7%
=
Net Income
€55.2m
/
Revenue
€182.3m
What is Cosmo Pharmaceuticals NV's current Net Margin?

The current Net Margin for Cosmo Pharmaceuticals NV is 32.7%, which is above its 3-year median of 22.3%.

How has Net Margin changed over time?

Over the last 3 years, Cosmo Pharmaceuticals NV’s Net Margin has decreased from 45.1% to 32.7%. During this period, it reached a low of -12.5% on Dec 31, 2023 and a high of 53.2% on Dec 31, 2024.

Back to Top